The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Lower-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer: A multicentric randomized phase III non-inferiority trial. This is an ASCO Meeting ...

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in ...

The impact of dietary patterns on inflammation and colon cancer risk: A retrospective study of 796 patients.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC ...

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

The effect of resting dendritic cells on overall survival in the hepatocellular carcinoma tumor microenvironment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and ...

A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO ...

Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors.

Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN ...